Kamada (Kamada) Debt-to-Equity : 0.04 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Kamada Debt-to-Equity?

Kamada's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.4 Mil. Kamada's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $7.4 Mil. Kamada's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $244.0 Mil. Kamada's debt to equity for the quarter that ended in Dec. 2023 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Kamada's Debt-to-Equity or its related term are showing as below:

KMDA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 0.14
Current: 0.04

During the past 13 years, the highest Debt-to-Equity Ratio of Kamada was 0.14. The lowest was 0.00. And the median was 0.03.

KMDA's Debt-to-Equity is ranked better than
84.35% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.285 vs KMDA: 0.04

Kamada Debt-to-Equity Historical Data

The historical data trend for Kamada's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Debt-to-Equity Chart

Kamada Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.03

0.14

0.12

0.04

Kamada Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.12	0.13	0.12	0.03	0.04

Competitive Comparison of Kamada's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kamada's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kamada's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Kamada's Debt-to-Equity falls into.

Kamada Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Kamada's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.384	+	7.438)	/	244.021
	=	0.04

Kamada's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.384	+	7.438)	/	244.021
	=	0.04

Kamada (NAS:KMDA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Kamada Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Kamada's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kamada (Kamada) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (NAS:KMDA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

KMDA:Israel

Address

2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402

Website

https://www.kamada.com

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.